ClinicalTrials.gg
TerminatedNCT05879718Updated Aug 11, 2026Results posted

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

A Phase 2 interventional study of Placebo and PF-06823859 in Lupus Erythematosus, Systemic and Lupus Erythematosus, Cutaneous, sponsored by Pfizer. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
365th of 407
8 · median 70
Started
2023
with 22 others
Phase 2
120 of 477
10 open now
Registered
379th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 365th largest by enrollment of the 407 interventional ones that give a count, is one of 23 that started in 2023, is one of 120 in phase 2, and was the 379th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.

This study is seeking for participants who:

  • are adults of 18 years of age or older.
  • are confirmed to have CLE or SLE with involvement of the skin.
  • have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8.

About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins).

At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60.

The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.

03

Conditions studied

  • Lupus Erythematosus, Systemic
  • Lupus Erythematosus, Cutaneous

Keywords

  • type 1 IFN gene signature, SLE, CLE
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher.
  • Participant has adequate intravenous infusion access per investigator's judgement
  • Willing to comply with study procedures including skin punch procedures.
  • Weight is greater than 40 kg and less than 130 kg.

Exclusion criteria

Exclusion Criteria:

  • Skin disorders other than CLE or SLE.
  • Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose .
  • Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.
  • Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
  • Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.
  • Have any or inflammatory disease that would interfere with interpretation of test results or clinical assessments.
  • History of disseminated herpes zoster/simplex or recurrent herpes zoster.
  • Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline.
  • Have evidence of active or latent infection of or C, known history of human immunodeficient virus () infection, or infected with Mycobacterium TB (active or latent TB)
  • Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Group 1

    PF-06823859

    Drug: PF-06823859

  • Placebo comparator
    Group 2

    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo (intravenous infusion)

  • PF-06823859 (intravenous infusion)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12

    Change from baseline GS was calculated as GS(t) - GS(0), where GS(t) was the gene signature score at Week 12 and GS(0) was the gene signature score at Baseline, where the GS(t) was calculated as the mean of log2 transformed counts per million reads from each of 13 genes in RNAseq, the higher GS indicated coordinated higher expression. There is no minimum/maximum limit to the GS score. Gene expression was quantified using RNA sequencing and summarized as log2-transformed counts per million mapped reads \[log2(CPM)\]. Higher values indicate higher normalized gene expression and without a bounded scale or defined minimum or maximum value.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease.

    Time frame: Baseline, Week 12

  2. Percent Change From Baseline in CLASI-A Score at Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Baseline, Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60

  3. Change From Baseline in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

  4. Percentage of Participants With Greater Than or Equal to (>=) 50 Percent Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=50 percent reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

  5. Percentage of Participants With >=4 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=4 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

  6. Percentage of Participants With >=7 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

    CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=7 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

  7. Change From Baseline in Physician Global Assessment (PhGA) Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

    PhGA score was assigned by physician as the number within the 0 to 100 millimeter range on visual assessment scale and provided a global characterization of disease. Higher scores indicating more severe disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

  8. Number of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0

    Laboratory test included activated partial thromboplastin time prolonged, alanine aminotransferase increased, alkaline phosphatase increased, anemia, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase (CPK) increased, cholesterol high, creatinine increased, hemoglobin increased, hypercalcemia, hyperkalemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell decreased. Laboratory test abnormalities were graded according to CTCAE v5.0; grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Participants with any laboratory abnormalities of CTCAE v5.0 grade 3 or more were reported in this outcome measure.

    Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60

  9. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). Clinically significant vital signs abnormalities were based on investigator's decision.

    Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60

  10. Number of Participants With Clinically Significant Electrocardiogram (ECG) Results

    ECG parameters included PR interval, QRS duration and QT interval using Fridericia's formula (QTcF) interval. Clinically significant abnormalities in ECG parameters were based on investigator's decision.

    Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60

  11. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Who Discontinued Study Due to TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were the AEs with onset dates on or after the start of the study intervention up to after last dose of study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other pre-specified criteria in protocol of the study or other important medical events. AEs included SAEs (if occurred) and all other AEs (including non-SAEs).

    Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60

07

Results

Posted Aug 11, 2026
Limitations and caveats
As per sponsor's decision to maintain company confidentiality, dose has not been disclosed in the record.

Participant flow

Initially participants were randomized to receive PF-06823859 or placebo in Period 1. In Period 2, participants in PF-06823859 group continued to receive the same, while participants who received placebo, depending upon the response, either continued receiving placebo (if responded to treatment) or were administered with PF-06823859 (non-responders). No participants continued to receive placebo in Period 2.

Period 1 (Day 1 to Pre-dose on Week 16)
Participant flow — Period 1 (Day 1 to Pre-dose on Week 16)
MilestonePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Started62
Completed62
Not completed00
Period 2 (Post-dose on Week 16-Week 48)
Participant flow — Period 2 (Post-dose on Week 16-Week 48)
MilestonePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Started62
Completed31
Not completed31
Withdrew: Study terminated by sponsor20
Withdrew: Withdrawal by subject11
Follow-up Phase (Post Week 48-Week 60)
Participant flow — Follow-up Phase (Post Week 48-Week 60)
MilestonePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Started62
Completed51
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12

Change from baseline GS was calculated as GS(t) - GS(0), where GS(t) was the gene signature score at Week 12 and GS(0) was the gene signature score at Baseline, where the GS(t) was calculated as the mean of log2 transformed counts per million reads from each of 13 genes in RNAseq, the higher GS indicated coordinated higher expression. There is no minimum/maximum limit to the GS score. Gene expression was quantified using RNA sequencing and summarized as log2-transformed counts per million mapped reads \[log2(CPM)\]. Higher values indicate higher normalized gene expression and without a bounded scale or defined minimum or maximum value.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · log2(CPM) units
Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12
log2(CPM) unitsPF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12-1.1 (-3.0 to 0.8)-1.6 (-4.9 to 1.8)
Statistical analysis
  • PF-06823859 Q4W Then PF-06823859 Q8W vs Placebo Q4W Then PF-06823859 Q8W · ANCOVA · p = =0.8243 · Least square mean difference: 0.5 · 90% CI -3.7 to 4.6Analysis of covariance (ANCOVA) was conducted for treatment comparison with baseline GS score as the covariate, and degrees of freedom was estimated using the Kenward-Roger approach.
SecondaryPercent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease.

Time frame:
Baseline, Week 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12
Percent changePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12-35.6 ± 21.28-8.2 ± 5.41
SecondaryPercent Change From Baseline in CLASI-A Score at Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Baseline, Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Mean · Percent change
Percent Change From Baseline in CLASI-A Score at Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60
Percent changePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 4-7.7 ± 32.09-44.3 ± 50.42
Week 8-22.8 ± 23.14-12.3 ± 5.16
Week 16-27.9 ± 41.011.7 ± 28.78
Week 20-29.8 ± 33.23-28.7 ± 15.99
Week 24-23.9 ± 39.72-22.2 ± 25.21
Week 32-22.8 ± 37.41-40.2 ± 50.67
Week 40-7.6 ± 34.49-64.0
Week 48-5.4 ± 34.93-68.0
Week 60-24.2 ± 39.22—
SecondaryChange From Baseline in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Mean · Score on a scale
Change From Baseline in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Score on a scalePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 4-1.8 ± 5.04-11.0 ± 12.73
Week 8-4.5 ± 4.28-3.0 ± 1.41
Week 12-7.0 ± 5.66-2.0 ± 1.41
Week 16-6.5 ± 8.123.0 ± 7.07
Week 20-5.8 ± 6.49-7.0 ± 4.24
Week 24-5.8 ± 8.54-5.5 ± 6.36
Week 32-4.8 ± 5.89-10.0 ± 12.73
Week 40-3.3 ± 7.27-16.0
Week 48-2.0 ± 6.98-17.0
Week 60-7.3 ± 9.02—
SecondaryPercentage of Participants With Greater Than or Equal to (>=) 50 Percent Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=50 percent reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of ParticipantsPF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 416.7 (0.9 to 58.2)50.0 (2.5 to 97.5)
Week 816.7 (0.9 to 58.2)0 (0.0 to 77.6)
Week 1233.3 (6.3 to 72.9)0 (0.0 to 77.6)
Week 1633.3 (6.3 to 72.9)0 (0.0 to 77.6)
Week 2033.3 (6.3 to 72.9)0 (0.0 to 77.6)
Week 2433.3 (6.3 to 72.9)0 (0.0 to 77.6)
Week 3220.0 (1.0 to 65.7)50.0 (2.5 to 97.5)
Week 4025.0 (1.3 to 75.1)100.0 (5.0 to 100.0)
Week 480 (0.0 to 52.7)100.0 (5.0 to 100.0)
Week 6033.3 (1.7 to 86.5)—
SecondaryPercentage of Participants With >=4 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=4 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With >=4 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of ParticipantsPF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 433.3 (6.3 to 72.9)50.0 (2.5 to 97.5)
Week 866.7 (27.1 to 93.7)50.0 (2.5 to 97.5)
Week 1266.7 (27.1 to 93.7)0 (0.0 to 77.6)
Week 1650.0 (15.3 to 84.7)0 (0.0 to 77.6)
Week 2066.7 (27.1 to 93.7)100.0 (22.4 to 100.0)
Week 2450.0 (15.3 to 84.7)50.0 (2.5 to 97.5)
Week 3260.0 (18.9 to 92.4)50.0 (2.5 to 97.5)
Week 4050.0 (9.8 to 90.2)100.0 (5.0 to 100.0)
Week 4825.0 (1.3 to 75.1)100.0 (5.0 to 100.0)
Week 6066.7 (13.5 to 98.3)—
SecondaryPercentage of Participants With >=7 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=7 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With >=7 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of ParticipantsPF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 416.7 (0.9 to 58.2)50.0 (2.5 to 97.5)
Week 833.3 (6.3 to 72.9)0 (0.0 to 77.6)
Week 1250.0 (15.3 to 84.7)0 (0.0 to 77.6)
Week 1650.0 (15.3 to 84.7)0 (0.0 to 77.6)
Week 2050.0 (15.3 to 84.7)50.0 (2.5 to 97.5)
Week 2450.0 (15.3 to 84.7)50.0 (2.5 to 97.5)
Week 3260.0 (18.9 to 92.4)50.0 (2.5 to 97.5)
Week 4025.0 (1.3 to 75.1)100.0 (5.0 to 100.0)
Week 4825.0 (1.3 to 75.1)100.0 (5.0 to 100.0)
Week 6066.7 (13.5 to 98.3)—
SecondaryChange From Baseline in Physician Global Assessment (PhGA) Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60

PhGA score was assigned by physician as the number within the 0 to 100 millimeter range on visual assessment scale and provided a global characterization of disease. Higher scores indicating more severe disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Reported as:
Mean · Millimetre
Change From Baseline in Physician Global Assessment (PhGA) Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
MillimetrePF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8W
Week 4-11.7 ± 23.07-5.5 ± 7.78
Week 8-18.5 ± 12.77-7.0 ± 9.9
Week 12-25.0 ± 23.1913.0 ± 19.8
Week 16-19.8 ± 28.5220.5 ± 27.58
Week 20-26.7 ± 26.8222.0 ± 31.11
Week 24-24.7 ± 30.7416.0 ± 24.04
Week 32-24.8 ± 35.175.5 ± 21.92
Week 40-25.3 ± 34.444.0
Week 48-21.0 ± 35.36-26.0
Week 60-37.7 ± 33.6130.0
SecondaryNumber of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0

Laboratory test included activated partial thromboplastin time prolonged, alanine aminotransferase increased, alkaline phosphatase increased, anemia, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase (CPK) increased, cholesterol high, creatinine increased, hemoglobin increased, hypercalcemia, hyperkalemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell decreased. Laboratory test abnormalities were graded according to CTCAE v5.0; grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Participants with any laboratory abnormalities of CTCAE v5.0 grade 3 or more were reported in this outcome measure.

Time frame:
For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0
ParticipantsPF-06823859 (at Q4W)PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)Placebo (at Q4W)Placebo (at Q4W) Then PF-06823859 (at Q8W)
Number of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.00100
SecondaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). Clinically significant vital signs abnormalities were based on investigator's decision.

Time frame:
For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsPF-06823859 (at Q4W)PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)Placebo (at Q4W)Placebo (at Q4W) Then PF-06823859 (at Q8W)
Number of Participants With Clinically Significant Vital Signs Abnormalities0000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Results

ECG parameters included PR interval, QRS duration and QT interval using Fridericia's formula (QTcF) interval. Clinically significant abnormalities in ECG parameters were based on investigator's decision.

Time frame:
For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Results
ParticipantsPF-06823859 (at Q4W)PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)Placebo (at Q4W)Placebo (at Q4W) Then PF-06823859 (at Q8W)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Results0000
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Who Discontinued Study Due to TEAEs

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were the AEs with onset dates on or after the start of the study intervention up to after last dose of study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other pre-specified criteria in protocol of the study or other important medical events. AEs included SAEs (if occurred) and all other AEs (including non-SAEs).

Time frame:
For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Who Discontinued Study Due to TEAEs
ParticipantsPF-06823859 (at Q4W)PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)Placebo (at Q4W)Placebo (at Q4W) Then PF-06823859 (at Q8W)
TEAEs4411
TESAEs0000
Discontinued study due to TEAEs0000

Adverse events

Collected over For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06823859 (at Q4W)0/6 (0%)0/6 (0%)4/6 (66.7%)
PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo (at Q4W)0/2 (0%)0/2 (0%)1/2 (50%)
Placebo (at Q4W) Then PF-06823859 (at Q8W)0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPF-06823859 (at Q4W)PF-06823859 (at Q4W) Then PF-06823859 (at Q8W)Placebo (at Q4W)Placebo (at Q4W) Then PF-06823859 (at Q8W)
Lacrimation increasedEye disorders0/60/61/20/2
COVID-19Infections and infestations0/61/60/21/2
Eye infectionInfections and infestations0/60/61/20/2
Iron deficiencyMetabolism and nutrition disorders0/60/60/21/2
Disturbance in attentionNervous system disorders0/60/61/20/2
ErythemaSkin and subcutaneous tissue disorders0/60/60/21/2
Skin lesionSkin and subcutaneous tissue disorders0/60/60/21/2
Dry eyeEye disorders0/61/60/20/2
Vision blurredEye disorders1/60/60/20/2
Angular cheilitisGastrointestinal disorders1/61/60/20/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8WTotal
Mean49.83 ± 7.2548.0 ± 15.5649.38 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)PF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8WTotal
Female415
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8WTotal
Hispanic or Latino213
Not Hispanic or Latino415
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06823859 Q4W Then PF-06823859 Q8WPlacebo Q4W Then PF-06823859 Q8WTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White527
More than one race000
Unknown or Not Reported000
08

Study locations

19 sites
  • The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham - School of Medicine
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, Department of Dermatology
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Mayo Clinic in Arizona - Scottsdale
    Scottsdale, Arizona 85259, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • Dermatology on Bloor - Research Toronto
    Toronto, Ontario M4W 2N4, Canada
  • Whitby Health Centre
    Whitby, Ontario L1P 0p9, Canada
  • University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"
    Chaïdári, Attikí 124 62, Greece
  • Ionos Dragoumi 5 Kaisariani
    Kaisarianí, Attikí 16121, Greece
  • Dermatological and Venereological Hospital Andreas Syggros
    Athens, 161 21, Greece
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Jun 2025, 22 months.

Results were first posted in Aug 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
May 30, 2023
StartActual
Jul 7, 2023
Primary completionActual
Jun 5, 2025
CompletionActual
Nov 18, 2025
Results first posted
Aug 11, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05879718
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Jul 7, 2023
Primary completion
Jun 5, 2025
Completion
Nov 18, 2025
Results posted
Aug 11, 2026
Last update
Aug 11, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazukibart

Start the discussion